Cargando…
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
BACKGROUND: Lenvatinib has been approved for use in the systemic treatment for unresectable hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy and safety of lenvatinib in patients with unresectable HCC who received sorafenib. METHODS: A total of 40 patients who received len...
Autores principales: | Chen, Yen-Yang, Wang, Chih-Chi, Liu, Yueh-Wei, Li, Wei-Feng, Chen, Yen-Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668202/ https://www.ncbi.nlm.nih.gov/pubmed/33240675 http://dx.doi.org/10.7717/peerj.10382 |
Ejemplares similares
-
Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019) -
Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis
por: Wu, Chia-Che, et al.
Publicado: (2018) -
Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
por: Oshita, Ko, et al.
Publicado: (2023) -
Does bariatric surgery influence plasma levels of fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus?
por: Huang, Hsien-Hao, et al.
Publicado: (2018) -
Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study
por: Chang, Te-Sheng, et al.
Publicado: (2021)